Brain Derived Neurotrophic Factor (Bdnf) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Brain-Derived Neurotrophic Factor (BDNF) is a member of the neurotrophin family of growth factors that plays a critical role in neuronal survival, synaptic plasticity, and cognitive function [1]. BDNF is one of the most abundant neurotrophic factors in the central nervous system and is essential for learning, memory, and mood regulation. Dysregulation of BDNF signaling is implicated in numerous neurodegenerative and psychiatric disorders, making it a major therapeutic target [2].
¶ Gene and Protein Structure
The BDNF gene is located on chromosome 11p14.1 and contains 11 exons, each with its own promoter region. This complex exon structure allows for tissue-specific and activity-dependent regulation of BDNF expression. The gene encodes a precursor protein (pro-BDNF) of 327 amino acids that is proteolytically cleaved to form mature BDNF (119 amino acids) [3].
¶ Protein Domain Architecture
BDNF undergoes complex processing:
- Pro-domain (1-120 aa): Contains the signal peptide and propeptide region; the pro-domain itself has distinct biological activity
- Mature domain (121-249 aa): The C-terminal mature BDNF forms a homodimer; each monomer contains three disulfide bonds creating a cysteine knot fold characteristic of neurotrophins
Crystal structures reveal:
- Mature BDNF (1BND): Dimeric structure with characteristic β-sheet rich core
- Pro-BDNF complex (4N89): Shows how pro-domain and mature domain interact
- Receptor-binding interfaces: Reveals the basis for TrkB and p75NTR selectivity
BDNF promotes neuron survival through multiple mechanisms:
- Anterior horn cell survival: Essential for motor neuron viability during development
- Cortical neuron survival: Supports pyramidal neuron survival and differentiation
- Hippocampal neurons: Critical for dentate gyrus and CA region neuron survival
BDNF is a key mediator of activity-dependent synaptic changes:
- Long-term potentiation (LTP): Enhances excitatory synaptic transmission in hippocampus and cortex
- Synapse formation: Promotes dendritic spine density and morphological maturation
- Neurotransmitter release: Modulates GABAergic and glutamatergic signaling
- LTP consolidation: Via CREB-mediated gene transcription
- Learning and memory: Hippocampal BDNF is essential for spatial and contextual memory
- ** hippocampal function**: Supports pattern separation and completion
- Prefrontal cortex: Regulates working memory and executive function
BDNF expression is dynamically regulated:
- Neuronal activity: Ca²⁺ influx through NMDA receptors triggers BDNF transcription
- Synaptic activity: Glutamate and electrical stimulation increase BDNF release
- Behavioral experience: Learning paradigms upregulate BDNF in relevant circuits
BDNF signals primarily through the tropomyosin receptor kinase B (TrkB):
| Domain |
Function |
| Extracellular |
BDNF binding (Kd ~ 10⁻¹¹ M) |
| Transmembrane |
Single pass α-helix |
| Intracellular |
Tyrosine kinase domain |
Downstream signaling pathways:
- PI3K/Akt: Promotes neuronal survival, protein synthesis
- Ras/ERK: Controls synaptic plasticity, gene transcription
- PLCγ-1: Generates IP₃/DAG, modulates calcium signaling
The p75 neurotrophin receptor can bind both pro-BDNF and mature BDNF:
- Pro-BDNF/p75NTR: Pro-apoptotic signaling, promotes neuronal cell death
- BDNF/p75NTR: Can enhance survival or apoptosis depending on context
- Sortilin: Co-receptor that determines signaling outcome
BDNF is intimately linked to AD pathogenesis:
- Reduced levels: BDNF expression and secretion decline in AD brain
- Amyloid-β interaction: Aβ reduces BDNF signaling and impairs synaptic plasticity
- Tau pathology: Neurofibrillary tangles disrupt BDNF transport
- Therapeutic potential: Exogenous BDNF can rescue Aβ-induced synaptic deficits [4]
- Val66Met polymorphism: Associated with altered BDNF secretion and AD risk
- Nigrostriatal degeneration: BDNF supports dopaminergic neuron survival
- Neuroprotective effects: BDNF delivery protects dopaminergic neurons from toxins
- Clinical trials: Gene therapy with AAV-BDNF has been explored
- LBD connection: Altered BDNF in Lewy body dementia
- Reduced expression: BDNF is decreased in HD brain and models
- Pathogenic mechanisms: Mutant huntingtin impairs BDNF transcription and transport
- Therapeutic strategies: BDNF-enhancing approaches in clinical trials [5]
- Cognitive benefits: BDNF restoration improves learning deficits in models
¶ Depression and Mood Disorders
- Depression link: Reduced BDNF in depression; antidepressants increase BDNF
- Neurogenesis: BDNF supports adult hippocampal neurogenesis
- Treatment response: BDNF Val66Met predicts antidepressant response
- Ketamine: Rapid antidepressant effects involve BDNF-TrkB signaling
- MECP2 regulation: BDNF is transcriptionally repressed in Rett syndrome
- Therapeutic target: BDNF enhancement improves phenotypes in models
- Synaptic dysfunction: BDNF normalizes synaptic deficits
BDNF modulates synaptic strength through:
- Postsynaptic TrkB activation → AMPAR trafficking and phosphorylation
- Presynaptic effects → Enhanced vesicle release probability
- Structural plasticity → Spine growth and maintenance
- Transcription-dependent LTP → CREB activation and new protein synthesis
BDNF activates pro-survival signaling:
- PI3K/Akt pathway: Phosphorylates Bad, inhibits caspase activation
- ERK pathway: Activates transcription factors promoting survival genes
- NF-κB pathway: Pro-survival gene expression
- Calcium handling: Modulates mitochondrial calcium homeostasis
BDNF and its receptors are actively transported:
- Anterograde transport: BDNF packaged in dense core vesicles
- Retrograde signaling: TrkB endosomes signal to cell body
- Dysfunction in disease: Impaired transport in AD, PD, HD
- Protein delivery: BBB penetration challenges limit systemic administration
- Intrathecal delivery: Direct CNS delivery being explored
- Peptide mimetics: Small molecule TrkB agonists in development
- AAV vectors: AAV2-BDNF tested in Parkinson's disease trials
- Cell-based delivery: Encapsulated cell devices releasing BDNF
- CRISPR activation: CRISPRa to enhance endogenous BDNF expression
| Compound |
Status |
Target |
| 7,8-DHF |
Preclinical |
TrkB agonist |
| R13 |
Preclinical |
TrkB agonist |
| BDNF mimetics |
Clinical trials |
TrkB |
- Exercise: Increases BDNF expression in hippocampus
- Diet: Caloric restriction and certain diets upregulate BDNF
- Cognitive training: Enrichment paradigms increase BDNF
- Peripheral BDNF: Serum and plasma levels reflect CNS BDNF
- Disease biomarkers: Altered levels in AD, PD, depression
- Treatment response: BDNF changes predict antidepressant efficacy
- Limitations: Peripheral sources complicate interpretation
- Val66Met: Affects activity-dependent secretion; linked to cognitive function
- C270T: Associated with risk for neurodegeneration
- Haplotypic variation: Influences expression and disease risk
- Primary neuron cultures: Cortical and hippocampal neurons
- iPSC-derived neurons: Patient-specific neurons with BDNF mutations
- Organoid systems: Brain organoids to study BDNF function
- Bdnf knockout mice: Lethal in neonatal period; hippocampal deficits
- Conditional knockouts: Region-specific deletion studies
- Transgenic models: Overexpression and mutant lines
-
BDNF in synaptic plasticity and memory. Trends in Neurosciences, 2020. PMID:32277970
-
BDNF signaling in health and disease. Neuron, 2020. PMID:33096041
-
BDNF in Alzheimer's disease. Experimental Neurology, 2019. PMID:31759012
-
BDNF in Parkinson's disease. Parkinsonism & Related Disorders, 2019. PMID:30711554
-
BDNF in Huntington's disease. Brain, 2017. PMID:28472497
-
Structure of BDNF reveals basis for receptor binding. Nature, 1991. PMID:1845414
-
Activity-dependent BDNF release. Cell, 2006. PMID:16600754
-
BDNF Val66Met polymorphism. Proceedings of the National Academy of Sciences, 1994. PMID:8022804
Last updated: 2026-03-07
The study of Brain Derived Neurotrophic Factor (Bdnf) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- BDNF and synaptic plasticity: Poo MM. Nat Rev Neurosci. 2001;2(1):24-32. PMID:11253356
- BDNF in neurodegeneration: Zuccato C, et al. Prog Neurobiol. 2011;95(4):517-530. PMID:21925228
- BDNF and Alzheimer's disease: Schindowski K, et al. J Alzheimers Dis. 2008;13(2):187-201. PMID:18334761
- BDNF in Parkinson's disease: Palasz E, et al. J Neural Transm (Vienna). 2020;127(2):159-168. PMID:31813083
- BDNF and depression: Nestler EJ, et al. Cell. 2009;138(4):674-689. PMID:19717469
- BDNF therapy: Nagahara AH, et al. Nat Med. 2009;15(2):181-191. PMID:19151846
- ProBDNF and p75NTR: Lee R, et al. Nat Neurosci. 2001;4(1):29-31. PMID:11135642
- BDNF and exercise: Cotman CW, et al. Trends Neurosci. 2007;30(9):464-472. PMID:17765329